Summary of the technology

The subject of the proposed offer is a new innovation of the Jagiellonian University - a new potential drug - poly(sodium 4-styrenesulfonates), (PSSNa), which can be used for treatment of FHV-1 and FCV infections.

Jagiellonian University

Details of the Technology Offer

A new drug for the prevention and treatment of feline herpesvirus type 1 (FhV-1) and feline calicivirus (FCV) infections


Potential drug:poly(sodium 4-styrenesulfonates) (PSSNa)

Application: prevention and treatment of feline herpesvirus type 1 (FHV-1) and feline calicivirus (FCV) infections

Feline upper respiratory tract disease (URTD) is a relatively mild condition, manifested by oral or nasal discharges, lethargy, pyrexia, conjunctivitis and sneezing. The disease, however, may progress to the severe sequelae, with potentially fatal outcome. This scenario is the most common in large animal communities, as catteries and shelters, where URTD is considered to be one of the major causes of death. Feline herpesvirus type 1 (FHV-1) and feline calicivirus (FCV) are considered to be the two major causes of URTDs.

Herpesvirusesinfect a wide variety of hosts, including mammals, reptiles, birds, amphibians, fish and bivales. In humans, herpesviruses are considered to be amongst the most prevalent pathogens. Feline herpesvirus type 1 (FHV-1)is present in the domestic cat population worldwide, causing viral rhinotracheitis (FVR) and ocular disease. It is estimated that 90% of cats are seropositive to this virus, whereas about 80% of infected animals establish lifelong lasting latency and ~45% of these shed
the virus. A half of immunologically naïve cats after primary exposure to FHV-1 develop URTD. The ocular herpetic disease manifested as acute conjunctivitis, neonatal conjunctivitis, chronic stromal keratitis, corneal sequestration and ulceration are also common, and may lead to permament eye damage or blindness.

Treatment options for human herpetic infections often involve use of specific nucleoside analogues (NA) such as acyclovir, penciclovir, idoxuridine, cidofovir or vidarabine. Unfortunately, the success of nucleotide analogues in human therapy does not translate to anti-FHV-1 therapies. Furthermore, some compounds are toxic on the systemic administration in cats.

Caliciviruses infect humans and animals, causing e.g. gastroenteritis, hemorrhages, respiratory tract or systemic disease. Feline calicivirus (FCV) is prevalent wordwide in the domestic cat population, and is commonly associated with oral ulceration, salivation, chronic stomatitis, mild respiratory or conjunctival disorders and limping syndrome. It has been, however, noted that some FCV isolates cause outbreaks with mortality rates reaching 40-60%. No adequate antiviral treatment is available. Previous reports show that FCV infection may be hampered in vitro by lithium chloride, mefloquine, protease and polymerase inhibitors, but these findings we not confirmed in clinic.

The new innovation of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of FHV-1 and FCV infections.

The main advantages of the offered drug are:

  • a new inhibitor of FHV-1 and FCV infections - poly(sodium 4-styrenesulfonates) (PSSNa);
  • established mechanism of antiviral activity of PSSNa;
  • confirmed antiviral activity and the ability to inhibit FHV-1 and FCV replication;
  • very low or undetectable toxicity of the drug in vitro and in vivo studies;
  • the possibility of use in the form of an ointment or solution/suspension for topical administration, as well as nasal or oral;
  • the ability to be included in a pharmaceutical composition with suitable diluents and/or excipients.

The offered invention is patent pending. Futher research and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for entities interested in commercial application of the invention.

Intellectual property status

  • Patent already applied for
  • Patent application number :PCT/PL2019/050071

Related Keywords

  • Biological Sciences
  • Biology / Biotechnology
  • Veterinary Medicine
  • Virus, Virology / Antibiotics / Bacteriology
  • Agriculture and Marine Resources
  • Genetic Engineering / Molecular Biology
  • Other
  • Animal health
  • Plant and animal health
  • Agriculture, Forestry, Fishing, Animal Husbandry and Related Products
  • Medical Health related
  • Other Medical/Health Related
  • Other Consumer Related (not elsewhere classified)
  • prevention
  • treatment
  • feline herpesvirus
  • infections
  • veterinary

About Jagiellonian University

Jagiellonian University, founded 1364, is the oldest university in Poland and one of the oldest worldwide. The research and teaching activities are conducted at 15 faculties, including the Medical College (Collegium Medicum). Over 3,700 researchers work at the university and the total number of students is about 50,000.

Jagiellonian University

Never miss an update from Jagiellonian University

Create your free account to connect with Jagiellonian University and thousands of other innovative organizations and professionals worldwide

Jagiellonian University

Send a request for information
to Jagiellonian University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support